Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

American Journal of Epidemiology

Volumn 151, Issue 12, 2000, Pages 1158-1171

  Myers, Evan R ^a,b   McCrory, Douglas C ^b,c   Nanda, Kavita ^a,b   Bastian, Lori ^b,c   Matchar, David B ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Cervical intraepithelial neoplasia; Cervix neoplasms; Models, theoretical; Papillomavirus, human

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; UNITED STATES; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX TUMOR; VIRUS INFECTION; WART VIRUS;

EID: 0033947903     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a010166     Document Type: Article

References (58)

1. Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755-63.
2. Ries L, Kosary C, Hankey B, et al. SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute, 1998.
3. Parkin DM. The epidemiological basis for evaluating screening policies. In: Franco E, Monsonego J, eds. New developments in cervical cancer screening and prevention. Oxford, England: Blackwell Science, 1997.
4. US Preventive Services Task Force. Guide to clinical preventive services. Baltimore, MD: Williams & Wilkins, 1996.
5. Kiviat N. Natural history of cervical neoplasia: overview and update. Am J Obstet Gynecol 1996;175:1099-104.
6. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5A):3-8.
7. Luce BR. Allocating costs and benefits in disease prevention programs: an application to cervical cancer screening. Washington, DC: US Congress, Office of Technology Assessment, 1981.
8. Fahs MC, Mandelblatt J, Schechter C, et al. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 1992;117:520-7.
9. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990;113:214-26.
10. Chesbro MJ, Everett WD. A cost-benefit analysis of colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear. Arch Fam Med 1996;5:576-81.
11. Muller C, Mandelblatt J, Schechter CB, et al. Costs and effectiveness of cervical cancer screening in elderly women. Washington, DC: US Congress, Office of Technology Assessment, 1990.
12. Sherlaw-Johnson C, Gallivan S, Jenkins D, et al. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J Clin Pathol 1994;47:430-5.
13. Prorok PC. Mathematical models and natural history in cervical cancer screening. In: Hakama M, Miller AB, Day NE, eds. Screening for cancer of the uterine cervix. Lyon, France: International Agency for Research on Cancer, 1986:185-98.
14. Koopmanschap M, Oortmarssen GV, Agt HV, et al. Cervical-cancer screening: attendance and cost-effectiveness. Int J Cancer 1990;45:410-15.
15. Matchar DB, Samsa GP, Matthews JR, et al. The Stroke Prevention Policy Model: linking evidence and clinical decisions. Ann Intern Med 1997;127:704-11.
16. McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evidence report/technology assessment no. 5. (Prepared by Duke University under contract no. 290-97-0014). Rockville, MD: Agency for Health Care Policy and Research, 1999. (AHCPR publication no. 99-E010).
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
18. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996;21:1-6.
19. Schiffman M, Bauer H, Hoover R, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
20. Cox J, Lorincz A, Schiffman M, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172: 946-54.
21. Luff RD. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. The Bethesda System Editorial Committee. Hum Pathol 1992; 23:719-21.
22. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994;14:52-8.
23. Merrill R, Feuer E. Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control 1996;7:544-52.
24. Lyon JL, Gardner JW. The rising frequency of hysterectomy: its effect on uterine cancer rates. Am J Epidemiol 1977;105: 439-43.
25. Mitchell M, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Mongr 1996;21:17-25.
26. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
27. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
28. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
29. Kataja V, Syrjanen K, Mantyjarvi R, et al. Prospective follow-up of cervical HPV infections: life table analysis of histopathological. cytological, and colposcopic data. Eur J Epidemiol 1989;5:1-7.
30. Kataja V, Syrjanen K, Syrjanen S, et al. Prospective follow-up of genital HPV infections: survival analysis of the HPV typing data. Eur J Epidemiol 1990;6:9-14.
31. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327: 1272-8.
32. Munoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23: 504-10.
33. Oortmarssen GV, Habbema J. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65.
34. Syrjanen K, Kataja V, Yliskoski M, et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 1992;79:675-82.
35. Pretorius R, Semrad N, Watring W, et al. Presentation of cervical cancer. Gynecol Oncol 1991;42:48-53.
36. Schwartz PE, Hadjimichael O, Lowell DM, et al. Rapidly progressive cervical cancer: the Connecticut experience. Am J Obstet Gynecol 1996;175:1105-9.
37. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health 1995;85:791-4.
38. Bearman DM, MacMillan JP, Creasman WT. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol 1987;69: 151-5.
39. Russell A, Shingleton HM, Jones WB, et al. Diagnostic assessments in patients with invasive cancer of the cervix: a national patterns of care study of the American College of Surgeons. Gynecol Oncol 1996;63:159-65.
40. Natarajan N, Mettlin C, Beart RW, et al. Design and analysis of national patterns of care surveys of the American College of Surgeons. Neoplasia 1985;2:5-10.
41. Mortality data from the National Vital Statistics System. National Center for Health Statistics. Hyattsville, MD (http://www.cdc.gov/nchs/about/major/dvs/mortdata.htm).
42. Lepine LA, Hillis SD, Marchbanks PA, et al. Hysterectomy surveillance - United States, 1980-1993. MMWR CDC Surveill Summ 1997;46(no. SS-4):1-14.
43. Kjerluff KH, Guzinski GM, Langenberg PW, et al. Hysterectomy and race. Obstet Gynecol 1993;82:757-64.
44. Fahey MT. Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-9.
45. Gustafsson L, Ponten J, Bergstrom R, et al. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997;71:159-65.
46. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
47. Carson HJ, DeMay RM. The mode ages of women with cervical dysplasia. Obstet Gynecol 1993;82:430-4.
48. Lawson HW, Lee NC, Thames SF, et al. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. Obstet Gynecol 1998;92: 745-52.
49. van Ballegooijen MV, van den Akker-van Marie ME, Warmerdam P, et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 1997;76:651-7.
50. Figueroa JP, Ward E, Luthi TE, et al. Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity. Sex Transm Dis 1995;22:114-18.
51. Brown A, Garber A. Cost-effectiveness of 3 methods to improve the sensitivity of Papanicolaou screening. JAMA 1999;281:347-53.
52. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implications for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. BMJ 1986;293: 659-64.
53. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence and mortality from cancer of the cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318:904-6.
54. Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999;180:571-7.
55. Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control 1992;3:125-36.
56. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996;65:768-73.
57. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3:1-204.
58. Goldie SJ, Weinstein MC, Kuntz KM, et al. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999;130:97-107.